AREXVY (recombinant, adjuvanted), the first vaccine to immunise and actively protect adults aged 60 years and older against lower respiratory tract disease caused by the respiratory syncytial virus (RSV), has been recommended by the European Medicines Agency for marketing authorisation in the European Union (EU).
In Europe, RSV causes an estimated 250,000 hospitalisations and 17,000 in-hospital deaths every year in people older than 65 years.
Arexvy contains an engineered version of the RSV fusion surface glycoprotein.
This protein is essential for RSV to infect the body and is also the main target of the antibodies generated to fight the infection.
The vaccine also contains an 'adjuvant', a substance to help strengthen the immune response to the vaccine.
When a person is given the vaccine, their immune system generates specific antibodies and T-cells that help prevent RSV infection.
Arexvy was evaluated under EMA's accelerated assessment mechanism because prevention of RSV infection in the elderly population is considered to be of major public health interest.
RSV is a common respiratory virus that usually causes mild, cold-like symptoms.
Most people recover within one to two weeks, but RSV can be serious in vulnerable people, including older adults and those with lung or heart disease and diabetes.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Apr 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Apr 23
Warning: Undefined variable $o_shortcode_atts in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1263
Warning: Undefined variable $output in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1266
